Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
Completed · Phase 2 · Has a placebo group
Conditions studied: Human Immunodeficiency Virus (HIV)
In brief
This is a multi-site, double-blinded, two-arm, two:one, randomized, trial comparing the safety of an intramuscular (IM) injection of TMC278 LA to a placebo given once every eight weeks over a 40 week period among sexually active, HIV- uninfected women.
Key facts
- Study ID
- NCT02165202
- Run by
- PATH
- People needed
- 136
- Starts
- 2014-10-01
- Expected to finish
- 2017-03-09
- Last updated by the study team
- 2018-08-27
Who can join
Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.
Where it is running
- New Jersey Medical School Clinical Research Center — Newark, New Jersey, United States
- Bronx Prevention Center — The Bronx, New York, United States
- Emavundleni Clinical Research Site — Cape Town, South Africa
- Spilhaus Clinical Research Site — Belgravia, Harare, Zimbabwe
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.